Russian determine skater claims constructive drug take a look at got here from granddad’s treatment

THE Russian determine skater on the coronary heart of a Winter Olympics doping controversy says a constructive medicine take a look at was because of her GRANDAD’S treatment.

Teenager Kamila Valieva reportedly had THREE totally different coronary heart medicine in her system when she failed a December dope take a look at.

The 15-year-old has been cleared to proceed competing on the Beijing Video games regardless of testing constructive for the angina drug trimetazidine.

And the Night Commonplace stories IOC doping professional Denis Oswald – who chaired the investigation into Russian dishonest at Sochi 2014 – stated the constructive pattern had been blamed on contamination from her grandad’s meds.

He stated: “Her argument was this contamination occurred with a product her grandfather was taking.”

Earlier this week the New York Instances reported that together with trimetazidine, one other two coronary heart therapies have been found in Valieva’s pattern.

Each, nevertheless, are NOT on the banned record.

Hypoxen and L-Carnitine confirmed up on the take a look at, with Valieva stated to have listed taking these on her doping management type.

US Anti-Doping Company Chief Govt Officer Travis Tygart stated within the report: “It’s a trifecta of gear – two of that are allowed, and one that’s not allowed.”

He added that when the three are used collectively, they ‘appear to be geared toward growing endurance, decreasing fatigue and selling higher effectivity in utilizing oxygen’.

Valieva leads the way in which within the ladies’s single skating following her untouchable rating of 82.16 within the brief programme on Tuesday.

If Valieva finishes within the high three of the person contest there will probably be no medal ceremony for the rostrum placers.

She has already gained gold within the workforce occasion for Russia, changing into the primary feminine determine skater to land a quadruple leap at a Video games.